Oscient Pharmaceuticals Corporation, a biopharmaceutical company, engages in the clinical development and commercialization of therapeutics to serve medical needs in the United States. Its lead product fluoroquinolone antibiotic FACTIVE tablets are used for the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. The company’s product also comprises Ramoplanin, a Phase II clinical trial completed product, which would be used for the treatment of clostridium difficile-associated disease. Oscient Pharmaceuticals’ preclinical development program includes an oral peptide deformylase inhibitor for the treatment of respiratory tract...